Trial | NCT00617474  Report issue

Official Title

The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    epoetin ...

  • Study Participants

    50
The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.
Study Started
Mar 31
2008
Primary Completion
Sep 30
2008
Anticipated
Study Completion
Mar 31
2009
Anticipated
Last Update
Mar 28
2008
Estimate

Drug Erythropoietin

sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.

Drug Placebo

placebo

1 Experimental

Group of patient with anemia, that treated by erythropoietin

2 Placebo Comparator

Patients group with anemia that treated by placebo

Criteria 

Inclusion Criteria:

Hb: >8 and <10 gr/dl
Age: >18 and <55 years
Cholesterol: <300 mg/dl
Triglyceride: <400 mg/dl
First Transplantation
Protocol of Immunosuppression: CSA + MMF + Prednisolone
Systolic BP: <14
Diastolic BP: <9

Exclusion Criteria:

History of specified cardiac disease
Second Transplantation or more
Hb: <7gr/dl
The patient needs to infusion of blood
Evidence of local or systemic infection, at the time of EPO injection
Presence of ATN / DGF after transplantation
Presence of emergent hypertension
High risk patients ( Like; PRA>50%)
Past history of hypersensitivity
No Results Posted